BiotechTube
Targazyme

Targazyme

San Diego, United States· Est.
targazyme.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Targazyme is pioneering a novel approach to cell and gene therapy by focusing on improving the delivery and engraftment of therapeutic cells. Its lead technology, TZ-101, acts as a 'GPS' for cells, aiming to multiply their effective delivery to disease sites by 400-1200%. The company has secured significant funding, built a strong IP portfolio, and assembled a seasoned leadership and advisory team to advance its platform towards clinical validation.

OncologyAutoimmune DiseasesNeurodegenerative Diseases

Technology Platform

Enzyme-based platform (TZ-101) that modifies therapeutic cells ex vivo to enhance their expression of ligands for selectins, molecules upregulated on endothelium in diseased tissues. This acts as a 'GPS' to multiply cell delivery to disease sites by 400-1200% and improve engraftment.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

Targazyme's platform addresses the critical delivery bottleneck in the rapidly growing cell & gene therapy market.
If successful, it could become a universal enabling technology, partnered across hundreds of cell therapy programs, particularly to unlock the challenging solid tumor and autoimmune disease segments.
The significant non-dilutive grant funding validates its scientific approach and extends its runway.

Risk Factors

The core technology is unproven in late-stage human trials, facing significant clinical development risk.
The company's partnership-dependent model ties its success to the progress of collaborators' underlying cell therapies.
It also faces competition from other groups developing solutions for cell delivery and trafficking.

Competitive Landscape

The competitive landscape includes companies and academic labs exploring various methods to improve cell therapy delivery, such as engineering cells to express chemokine receptors, using oncolytic viruses to modify the tumor microenvironment, and developing bispecific antibodies. Targazyme's differentiation lies in its enzyme-based, selectin-focused approach, which aims to be a universal, one-step ex vivo modification applicable to any cell type.

More companies in Cell & Gene Therapy →More companies in United States →